Interleukin-6 and oncostatin M stimulation of proliferation of prostate cancer 22Rv1 cells through the signaling pathways of p38 mitogen-activated protein kinase and phosphatidylinositol 3-kinase
- 14 February 2005
- journal article
- research article
- Published by Wiley in The Prostate
- Vol. 64 (2) , 209-216
- https://doi.org/10.1002/pros.20235
Abstract
INTRODUCTION Interleukin‐6 (IL‐6) is a pleiotropic regulator of prostate cancer cell growth. Oncostatin M (OSM), an IL‐6‐type cytokine, affects the growth of prostate cancers in a paracrine and autocrine manner. In order to understand better the mechanisms controlling proliferation and intracellular signaling by these cytokines in advanced prostate carcinoma, we performed studies in 22Rv1 cells derived from the relapsed xenograft CWR22R. METHODS Expression of IL‐6 and OSM receptors (OSMR‐β) and elements of signal transduction pathways in 22Rv1 cells were investigated by RT‐PCR. Proliferation was assessed by cell counting after treatment with either IL‐6 or OSM. IL‐6 secretion was measured in conditioned medium from 22Rv1 cells by ELISA. Expression and phosphorylation status of signal transducers and activators of transcription factor (STAT) 3, mitogen‐activated protein kinases (MAPK) p44/p42 and p38, and protein kinase B (Akt) was investigated by Western blot. RESULTS 22Rv1 cells express both subunits of the IL‐6 receptor (gp80 and gp130) and leukemia inhibitory factor receptor‐β (LIFR‐β) but not OSMR‐β. Their proliferation was stimulated by IL‐6 or OSM and the maximal effect was observed at a concentration of 10 ng/ml of either cytokine. Interestingly, neither IL‐6 nor OSM induced phosphorylation of STAT3. OSM modestly increased the phosphorylation of p38 and both cytokines exerted an effect on Akt phosphorylation. CONCLUSIONS IL‐6 and OSM stimulate proliferation of 22Rv1 cells, at least in part through activation of the phosphatidylinositol 3‐kinase (PI 3‐K) signaling pathway. Our data provide additional evidence for the growth‐stimulatory role of IL‐6 and related cytokines in advanced prostate cancer and may serve as a basis for the development of novel experimental therapies.Keywords
This publication has 24 references indexed in Scilit:
- Steroid hormonal regulation of growth, prostate specific antigen secretion, and transcription mediated by the mutated androgen receptor in CWR22Rv1 human prostate carcinoma cellsMolecular and Cellular Endocrinology, 2004
- Accelerated in Vivo Growth of Prostate Tumors that Up-Regulate Interleukin-6 Is Associated with Reduced Retinoblastoma Protein Expression and Activation of the Mitogen-Activated Protein Kinase PathwayThe American Journal of Pathology, 2003
- Prostaglandin E2 Stimulates Prostatic Intraepithelial Neoplasia Cell Growth through Activation of the Interleukin-6/GP130/STAT-3 Signaling PathwayBiochemical and Biophysical Research Communications, 2002
- Interleukin-6 Is an Autocrine Growth Factor in Human Prostate CancerThe American Journal of Pathology, 2001
- Anti‐interleukin‐6 monoclonal antibody induces regression of human prostate cancer xenografts in nude miceThe Prostate, 2001
- Interleukin-6 activates phosphatidylinositol-3 kinase, which inhibits apoptosis in human prostate cancer cell linesThe Prostate, 2000
- A new human prostate carcinoma cell line, 22Rv1In Vitro Cellular & Developmental Biology – Animal, 1999
- Stromal cells from human benign prostate hyperplasia produce a growth-inhibitory factor for LNCaP prostate cancer cells, identified as interleukin-6International Journal of Cancer, 1996
- Interleukin-6: A candidate mediator of human prostate cancer morbidityUrology, 1995
- A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye bindingAnalytical Biochemistry, 1976